![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
4β2 Nicotinic Acetylcholine ReceptorsEli Lilly & Company, Lilly Research Centre, Windlesham, Surrey, United Kingdom (R.Z., A.J.M., E.A.F., L.M.B., A.C.W., E.S.); Eli Lilly & Company, Lilly Corporate Center, Indianapolis, Indiana (D.Z., C.D., B.A.H.); and School of Life Sciences, Oxford Brookes University, Oxford, United Kingdom (A.L.C., M.M., I.B.).
Received for publication January 9, 2008.
Accepted for publication March 24, 2008.
 |
Abstract |
|---|
 Top Abstract Materials and MethodsResultsDiscussionReferences |
|---|
4β2 nicotinic acetylcholine receptors (nAChRs), implying that it desensitizes 4β2 nAChRs without first activating them. This unusual pharmacological property of sazetidine-A makes it, potentially, an excellent research tool to distinguish between the role of activation and desensitization of 4β2 nAChRs in mediating the central nervous system effects of nicotine itself, as well as those of new nicotinic drugs. We were surprised to find that sazetidine-A potently and efficaciously stimulated nAChR-mediated dopamine release from rat striatal slices, which is mediated by 4β2* and 6β2* subtypes of nAChR. The agonist effects on native striatal nAChRs prompted us to re-examine the effects of sazetidine-A on recombinant 4β2 nAChRs in more detail. We expressed the two alternative stoichiometries of 4β2 nAChR in Xenopus laevis oocytes and investigated the agonist properties of sazetidine-A on both 4(2)β2(3) and 4(3)β2(2) nAChRs. We found that sazetidine-A potently activated both stoichiometries of 4β2 nAChR: it was a full agonist on 4(2)β2(3) nAChRs, whereas it had an efficacy of only 6% on 4(3)β2(2) nAChRs. In contrast to what has been published before, we therefore conclude that sazetidine-A is an agonist of native and recombinant 4β2 nAChRs but shows differential efficacy on 4β2 nAChRs subtypes.
subunits (2-10) and three different types of nAChR β subunits (β2-β4), in the nervous system. Some of these subunits form homopentameric receptors when expressed in heterologous expression systems (7, 8, and 9), whereas other subunits assemble into heteropentameric structures with various combinations of and β subunits. Different subunit combinations yield functional nAChRs that differ considerably in their functional and pharmacological properties (Luetje and Patrick, 1991
; Papke, 1993; Chavez-Noriega et al., 1997). The predominant subtype of nAChR in the central nervous system contains 4 and β2 subunits (4β2*) (Flores et al., 1992; Picciotto et al., 2001). The asterisk indicates that besides 4 and β2 subunits, there may be additional subunits coassembled in native 4β2 receptors. These 4β2* nAChRs are possible targets for drugs to treat pain, nicotine addiction, attention deficit disorders, and such diseases as Alzheimer's and Parkinson's (Lloyd and Williams, 2000; Jensen et al., 2005). The exact subunit composition of 4β2* nAChRs in the brain is still largely unknown.
Epibatidine, a chemical originally isolated from the skin of the Ecuadorian poison-arrow frog, Epipedobates tricolor, has been shown to act as a nAChR agonist and to cause profound analgesic effects (Badio and Daly, 1994). However, apart from showing strong analgesic effects, epibatidine also causes a wide range of severe side effects, possibly because of its lack of subtype specificity, which makes it far too toxic to be considered for clinical use (Rupniak et al., 1994; Sullivan et al., 1994a,b; Boyce et al., 2000). In the last few years, significant efforts have been directed toward the discovery of new nAChR-based analgesics with improved safety profiles. One focus has been on selectivity [i.e., trying to identify nAChR agonists that selectively activate those nAChR subtypes that are involved in causing the positive analgesic effect (mainly 4β2*) but don't activate those nAChRs (e.g., 3β4, 1β1
) that are involved in mediating the most severe side effects (Ji et al., 2007)]. In addition, variations in potency and efficacy of selective 4β2 nAChR agonists have been explored. Along these lines, sazetidine-A has been reported to bind selectively and with high affinity to 4β2 nAChRs (Xiao et al., 2006). The reported functional properties of this compound, however, are uncommon. It has been shown that sazetidine-A can potently desensitize 4β2 nAChRs without activating them. It has been suggested that sazetidine-A could represent a new class of nicotinic cholinergic drugs with a novel mechanism of action, branded as "silent desensitizers." On the other hand, recent reports suggest in vivo efficacy strikingly similar to more conventional 4β2 agonists. For example, in rats that were trained to discriminate nicotine from saline, sazetidine-A was demonstrated to fully substitute for nicotine as discriminative stimulus in a drug discrimination assay (Xiao et al., 2007). Furthermore, sazetidine-A was found to be more potent and efficacious than epibatidine in the formalin test for persistent pain (Cucchiaro et al., 2007). Because of the intriguing discrepancy between the in vitro and in vivo reports, we decided to characterize sazetidine's in vitro pharmacological properties in more detail. We were surprised to find that sazetidine-A was a potent agonist on native 4β2* nAChRs mediating dopamine release from rat striatal slices. Further in vitro characterization of the compound on distinct human recombinant 4β2 nAChR stoichiometries revealed that the receptors with the 4(2)β2(3) stoichiometry, are also potently and efficaciously activated by sazetidine-A. Our results, showing that sazetidine-A is a potent agonist at native and recombinant 4β2 nAChRs, reconcile the apparent discrepancy between in vitro and in vivo results previously reported.
|
|
Materials and Methods |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
) with modification on the step of Sonogashira coupling reaction. Thus, a mixture of (S)-5-bromo-3-{[1-(t-butoxycarbonyl)-2-azetinyl]-methoxy}pyridine (1.213 g, 3.53 mmol), potassium carbonate (1.22 g, 8.84 mmol), triphenylphosphine (148 mg, 0.57 mmol), copper(I) bromide (81 mg, 0.57 mmol), and palladium on carbon (100 mg) in 1,2-dimethoxyethane (14 ml) and water (14 ml) was stirred at room temperature for 30 min under N2, then 5-hexyn-1-ol (867 mg, 8.84 mmol) was added to the mixture. The reaction was heated to reflux for 68 h. The reaction was diluted with EtOAc, the organic layer was separated, and the aqueous layer was extracted with EtOAc twice. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated. The residue was purified by chromatography (silica gel) eluting with EtOAc/hexanes 50 to 80% to afford (S)-5-(5-hexyn-1-ol)-3-{[1-t-(butoxycarbonyl)-2-azetidinyl]-methoxy}pyridine as a colorless oil (1.162 g, 91.2%). 1H NMR data match the reported data on this compound. Deprotection of (S)-5-(5-hexyn-1-ol)-3-{[1-t-(butoxycarbonyl)-2-azetidinyl]-methoxy}pyridine provided Sazetidine-A. The purity of the final product is 100% as measured by liquid chromatography-mass spectrometry. An alternative batch of sazetidine-A was purchased from Alexis Biochemicals (Nottingham, UK).
[3H]Epibatidine Binding to 4β2 and 3β4 nAChRs Stably Expressed in HEK-293 Cells
Membrane Preparation. HEK293 cell lines stably expressing the nicotinic 4β2 or 3β4 receptors were maintained in Dulbecco's modified Eagle's medium/Nutrient Mix F-12 (3:1; Invitrogen, Carlsbad, CA) supplemented with 5% fetal bovine serum (Invitrogen), 250 µg/ml G418 (Geneticin), and 20 mM HEPES (Invitrogen). Membranes from large-scale cell production were prepared as described previously (Smith et al., 2007). In brief, cell pastes were homogenized in 4 volumes of buffer (50 mM Tris-HCl, 150 mM NaCl, and 5 mM KCl, pH 7.4). The homogenate was centrifuged twice (40,000g, 10 min, 4°C), and the pellets were resuspended in 4 volumes of Tris-HCl buffer after the first spin and 8 volumes after the second spin. The resuspended homogenate and the supernatant were centrifuged again (100g, 10 min, 4°C and 40,000g, 20 min, 4°C, respectively), and the pellet was resuspended in Tris-HCl buffer supplemented with 10% (w/v) sucrose. The membrane preparation was stored in 1-ml aliquots at -80°C until tested. The protein concentration of the membrane preparation was determined using a BCA protein assay reagent kit (Pierce, Rockford, IL).
Nicotinic Receptor Radioligand Binding Scintillation Proximity Assay. Scintillation proximity assay radioligand binding assays were modified from methods described previously (Badio and Daly, 1994; Gerzanich et al., 1995). Both 4β2 and 3β4 assays were performed in 96-well plates in a final volume of 250 µl of Tris-HCl buffer (50 mM Tris-HCl, 150 mM NaCl, and 5 mM KCl, pH 7.4) using the following conditions: 2 nM [3H]epibatidine (53 Ci/mmol; GE Healthcare, Chalfont St. Giles, Buckinghamshire, UK); 1 mg/well wheat germ agglutinin-scintillation proximity assay beads (GE Healthcare); and 5 µg/well of membrane protein. Nonspecific binding (<10% for both assay types) was determined using 100 µM concentrations of unlabeled epibatidine. Reactions were allowed to equilibrate for 3 h at room temperature before reading on a Wallac counter (PerkinElmer Life and Analytical Sciences). Data were analyzed as Ki values using a four-parameter logistic curve fitting program (ActivityBase v5.3.1.22l IDBS, Guildford, Surrey, UK).
[3H]Dopamine and [3H]Noradrenaline Release from Rat Native Tissue
Male Lister hooded rats (250-350 g) were killed by exposure to CO2 followed by cervical dislocation. Striata from two rats or hippocampi from three rats were dissected and chopped three times at 150 µm using a McIlwain tissue chopper, each time rotating the tissue through 60°. Slices were dispersed in Krebs bicarbonate buffer (118 mM NaCl, 2.4 mM KCl, 2.4 mM CaCl2·2H2O, 1.2 mM KH2PO4, 1.2 mM MgSO4·7H2O, 25 mM NaHCO3, 10 mM glucose, 1 mM ascorbic acid, gassed with 5% CO2/95% O2 for 1 h, pH 7.4), including 10 µM pargyline, and were incubated with [3H]dopamine (20-23 µCi/ml; 50 nM) or [3H]noradrenaline (56-60 µCi/ml; 100 nM) for 30 min at 37°C. After loading, slices were washed with Krebs buffer containing 1 µM nomifensine and 10 µM pargyline. After the final wash, slices were resuspended in Krebs buffer, and a 100-µl aliquot was placed in each well of a 96-well GF/C filter plate (Millipore, Billerica, MA). Buffer was removed to waste, and 70 µl of buffer was added to each well before incubation at 37°C for 5 min, after which the buffer was removed into a 96-well collection plate. Slices were then stimulated for 5 min with agonist (70 µl/well), after which the stimulating buffer was removed into another 96-well collection plate. Optiphase Supermix (PerkinElmer Life and Analytical Sciences) scintillation fluid (170 µl) was added to each well of the collection plates before the plates were heat-sealed and radioactivity was quantified using a 1450 Microbeta 96-well plate counter (counting efficiency, 25%; PerkinElmer Life and Analytical Sciences). Radioactivity remaining in the slices was measured by digestion of the tissue in 1 M HCl for 1 h with release quantified as above. Release of [3H]dopamine or [3H]noradrenaline was expressed as a fraction of the total radioactivity contained within the slices at the time of stimulation. Data points are shown as mean ± S.E.M. of at least three independent experiments (each with four or more replicates). Curves were fitted using the four-parameter Hill equation using Sigmaplot 9.0. -Conotoxin MII was purchased from Tocris Bioscience (Bristol, UK); dihydro-β-erythroidine and mecamylamine were purchased from Sigma-Aldrich (Poole, UK).
|
). Human 4 and β2 subunit cDNAs, ligated into the pCI (Promega) expression vector, were dissolved in distilled water at a concentration of 1 µg/µl (spectrophotometric and agarose gel electrophoresis determinations). Mixtures of 4 and β2 cDNA at 1:10, 10:1 ratios were injected into the nuclei of oocytes in a volume of 18.4 nl/oocyte, using a Nanoject Automatic Oocyte Injector (Drummond, Broomall, PA). The total amount of cDNA injected per oocyte was kept constant at 2 ng. After injection, oocytes were incubated at 18°C for 2 to 5 days in a modified Barth's solution containing 88 mM NaCl, 1 mM KCl, 2.4 mM NaHCO3, 0.3 mM Ca(NO3)2, 0.41 mM CaCl2, 0.82 mM MgSO4, 15 mM HEPES, and 5 mg/l neomycin, pH 7.6. Recordings were performed 3 to 5 days after injection. Oocytes were placed in a 0.1-ml recording chamber and perfused with modified Ringer solution (150 mM NaCl, 2.8 mM KCl, 10 mM HEPES, 1.8 mM BaCl2, pH 7.2, adjusted with NaOH) at a rate of 10 ml/min. We chose a nominally Ca2+-free solution to minimize the contribution to the response of Ca2+-gated chloride channels that are endogenous to the X. laevis oocyte and may be activated by Ca2+ entry through the nAChRs.
Oocytes were impaled by two agarose-cushioned microelectrodes filled with 3 M KCl (0.5-2.0 M
) and voltage-clamped at -60 mV using a GeneClamp 500B amplifier and pClamp 6 software (Molecular Devices, Sunnyvale, CA). Typically, traces were filtered at 1 kHz during recording and digitized at 0.5-5kHz using the DigiData 1200 interface (Axon Instruments, CA). All experiments were carried out at room temperature. Agonist concentration-response curves were obtained by normalizing agonist-induced responses to the control responses induced by 1 mM ACh (a near-maximum effective concentration at receptors obtained with 10:1 4/β2 cDNA transfecting ratios and an EC100 concentration at receptors expressed by oocytes injected with 1:10 4/β2 cDNA ratios). A minimum interval of 4 min was allowed between agonist applications, as this was found to be sufficient to ensure reproducible recordings.
Data Analysis Concentration-response curves were fitted by a nonlinear least-squares algorithm according to the equation i = imax/(1 + {EC50/[conc]}n), in which imax is the maximum obtainable peak current, EC50 is the concentration of the agonist that elicits 50% of the maximum obtainable peak current, and n is the slope factor. Results are expressed as mean ± S.D.
|
Results |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
4β2 versus human recombinant 3β4 nAChRs was evaluated in competition experiments using [3H]epibatidine as the radioligand. Using standard saturation binding methods, the Kd values of epibatidine for 4β2 and 3β4 membranes were determined to be 0.24 and 0.37 nM, respectively. Sazetidine-A displaced [3H]epibatidine binding to 4β2 with a mean relative IC50 of 2.6 ± 1.2 nM, a calculated mean Ki of 0.26 ± 0.11 nM, and a mean Hill coefficient of 0.85 ± 0.03. On the other hand, sazetidine-A displaced [3H]epibatidine binding to 3β4 with a mean relative IC50 of 365 ± 59 nM, a calculated mean Ki of 54 ± 5 nM, and a mean Hill coefficient of 0.85 ± 0.11 (Fig. 2). We therefore confirmed previously published binding results (Xiao et al., 2006) showing that sazetidine-A binds with significantly higher affinity to 4β2 than 3β4, and extended this finding to human receptors. It is worth noting, however, that the selectivity ratios between human receptors (current study) seem to be smaller than that for rat receptors (Xiao et al., 2006). Species specificity issues, specifically between human and rat 3β4 nAChRs, have recently been highlighted by our laboratory (Young et al., 2007).
Neurotransmitter Release Assays. Binding assays per se cannot predict whether a ligand acts as an agonist or an antagonist at a particular receptor. Functional assays with sazetidine-A on native rat nAChRs have therefore been performed to answer this specific question. Dopamine release from rat striatal slices is mediated by the activation of native 4β2* and 6β2* nAChRs (Mogg et al., 2004; Salminen et al., 2004; Grady et al., 2007; Smith et al., 2007). We found that sazetidine-A acts as a potent and efficacious agonist in evoking [3H]dopamine release from rat striatal slices (EC50 = 1.1 ± 0.3 nM; Emax = 96 ± 6%; n = 3; Fig. 3a). Both the nicotinic antagonists mecamylamine (n = 3) and dihydro-β-erythroidine (n = 3) inhibited sazetidine-A-evoked dopamine release, demonstrating the nicotinic nature of the sazetidine-A-evoked response. -Conotoxin MII is a nicotinic antagonist that distinguishes between 4β2* and 6β2* nAChRs. 4β2* nAChRs are resistant to 100 nM toxin, whereas 6β2* nAChRs are fully blocked by the same toxin concentration (Salminen et al., 2004). At the concentration of 100 nM -conotoxin MII reduced the Emax but had no significant effect on the EC50 of sazetidine-A. The estimates of EC50 and Emax values in the presence of 100 nM -contotoxin MII are 0.27 ± 0.5 nM and 49 ± 1% (n = 3), respectively, indicating that 52% of the sazetidine-A induced DA release is mediated by -conotoxin MII-resistant (4β2*) nAChRs and that 48% of the sazetidine-A-induced DA release is mediated by -conotoxin MII-sensitive (6β2*) nAChRs.
|
3β4* nAChRs (Luo et al., 1998; Anderson et al., 2000). We found that sazetidine-A also evoked noradrenaline release but with much lower potency and lower efficacy (EC50 = 4.5 ± 2.6 µM, and Emax = 55 ± 7%; n = 3) than it evoked dopamine release from striatal slices. The nicotinic antagonists mecamylamine and dihydro-β-erythroidine both inhibited sazetidine-A-evoked [3H]dopamine release (Fig. 3b), confirming that sazetidine-A effects are mediated by nAChR activation, rather than by other means. These neurotransmitter release experiments from native rat tissues demonstrate that sazetidine-A is a potent agonist of native rat 4β2* and 6β2* receptors but a weak agonist of native 3β4* nAChRs.
To verify that the agonist effects of sazetidine-A observed are not caused by the specific batch of sazetidine-A used, we also tested another, commercially available sazetidine-A. The EC50 and Emax values obtained with this new source of sazetidine-A were 0.85 ± 0.28 nM and 94 ± 3% (n = 3), respectively, in the dopamine release assay from striatal slices and 24 ± 6 µM and 38 ± 3% (n = 3), respectively, in the noradrenaline release assay from hippocampal slices (data not shown). These data are consistent with the data obtained with the sazetidine-A that we synthesized in house.
Oocyte Expression Experiments. Based on the intriguing new finding described above, we decided to revisit the functional properties of sazetidine-A with the aim of 1) confirming that the agonist effects on 4β2* nAChRs we saw were not specific to the rat but also translate to the human receptors and 2) understanding better the biophysical basis for the absence of agonism previously reported (Xiao et al., 2006). We chose to use the X. laevis oocyte expression system, combined with the two-electrode voltage clamp technique, because this is a very sensitive technique that can also detect very partial agonism. In addition, the oocyte expression system can be used to study different subunit stoichiometries of 4β2 nAChR simply by varying the 4 and β2 subunit cDNA ratio that is injected before the experiments. 4(2)β2(3) and 4(3)β2(2) nAChRs can then be studied in isolation and, importantly, have previously been shown to have distinct pharmacology (Moroni et al., 2006; Zwart et al., 2006). Figure 4a shows the concentration-dependence of the peak amplitudes of currents induced by sazetidine-A on both subtypes of 4β2 nAChR. Various concentrations of sazetidine-A and the maximally effective concentration of 1 mM ACh (Moroni et al., 2006) were alternately applied to control for rundown of the response. Sazetidine-A-induced current amplitudes were normalized to the amplitude of 1 mM ACh-induced currents. Mean concentration-response curves calculated from the parameters obtained by fitting the equation under Data Analysis to the data of individual experiments are depicted in Fig. 4a. The mean EC50, slope factor, and Emax of the concentration-response curves for sazetidine-A (n = 3) are 6.1 ± 1.2 nM, 1.0 ± 0.1, and 98 ± 9%, respectively, for 4(2)β2(3) nAChRs and 2.4 ± 1.2 nM, 1.3 ± 0.4, and 5.8 ± 1.1%, respectively, for 4(3)β2(2) nAChRs. Figure 4b shows examples of currents induced by 1 mM ACh and 100 nM sazetidine-A, which are maximally effective concentrations for the two agonists at 4(2)β2(3) nAChRs. Sazetidine-A was clearly able to evoke currents of approximately the same size as those induced by ACh. On the other hand, Fig. 4c shows examples of currents induced by 1 mM ACh and 1 µM sazetidine-A, which are maximally effective concentrations for the two agonists at 4(3)β2(2) nAChRs. These traces highlight that sazetidine-A is a very poorly efficacious agonist at 4(3)β2(2) nAChRs.
|
|
Discussion |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
), sazetidine-A is a potent and efficacious agonist of both human recombinant and rat native 4β2* nAChRs.
Addition of sazetidine-A to rat striatal slices potently and efficaciously stimulated dopamine release, an effect blocked by the nicotinic antagonists dihydro-β-erythroidine and mecamylamine. It is noteworthy that 100 nM -conotoxin MII, a nicotinic antagonist that distinguishes 4β2* nAChRs from 6β2* nAChRs, reduced the Emax of the concentration-response curve of sazetidine-A by approximately 48%, indicating that approximately half of the sazetidine-A-induced dopamine release is mediated by 6 subunit-containing nAChRs. Thus, besides being an agonist of 4β2* nAChRs, sazetidine-A is also a potent agonist of 6 subunit-containing nAChRs.
In particular, the agonistic effects on 4β2* nAChRs were quite surprising, specifically because in SH-EP1 cells stably transfected with recombinant human 4β2 nAChRs, sazetidine-A does not induce any measurable agonistic effect (Xiao et al., 2006). In contrast, prolonged (but not acute) applications of low concentrations of sazetidine-A potently desensitized 4β2 nAChRs expressed in the same cells, an effect more typically associated with agonists. This led the authors to suggest that sazetidine-A is a "silent desensitizer" of 4β2 nAChRs (Xiao et al., 2006).
To identify the molecular basis for this apparent discrepancy, we performed more electrophysiological experiments. In the X. laevis oocyte expression system the expression of 4β2 nAChRs subtypes with high- and low-sensitivity to ACh can be manipulated by transfecting the oocytes with cDNAs encoding the 4 and β2 subunits in different ratios (Zwart and Vijverberg, 1998; Moroni et al., 2006; Zwart et al., 2006). When 4 and β2 subunits are injected in the 1:10 4/β2 ratio, the oocytes will express a homogeneous population of 4β2 nAChRs with high sensitivity to ACh, whereas injection of 4 and β2 subunits in the 10:1 ratio results in the expression of a homogeneous population of 4β2 nAChRs with low sensitivity to ACh. When sazetidine-A was tested on both 4β2 nAChR subtypes, it was found to be a potent and efficacious agonist of the 4β2 nAChRs that have high sensitivity to ACh. It must be stressed, however, that sazetidine-A also potently activated the second isoform of 4β2 nAChRs with low sensitivity to ACh but with very low efficacy.
The question then arises as to why Xiao et al. (2006) observed no agonist effect of sazetidine-A on their heterologously expressed 4β2 nAChRs. First of all, the fact that recombinant 4 and β2 nAChR subunits assemble in more than one 4β2 nAChR stoichiometry was totally neglected, and the subtypes of 4β2 nAChRs expressed in SH-EP1 cells were not verified. This is an important factor, because potencies and efficacies of 4β2 nAChR ligands depend heavily on the subunit stoichiometry of 4β2 nAChRs (Zwart and Vijverberg, 1998; Nelson et al., 2003; Zhou et al., 2003; Karadsheh et al., 2004; Khiroug et al., 2004; López-Hernández et al., 2004; Briggs et al., 2006; Moroni et al., 2006; Zwart et al., 2006; Tapia et al., 2007). One possibility is that the SH-EP1 cells used by Xiao et al. (2006) express mainly 4(3)β2(2) nAChRs that have low affinity for ACh. In combination with the poorly sensitive biochemical rubidium efflux assay used, the very partial agonist effect of sazetidine-A on the low-affinity subtype of 4β2 nAChR might have been missed. However, two reports from another laboratory show concentration-response curves for ACh in the same human 4β2 SH-EP1 cell line using a rubidium efflux assay with EC50 values of approximately 1 µM (Eaton et al., 2003; Kuo et al., 2005), suggesting that these cells might express 4(2)β2(3) nAChRs that have high affinity for ACh. A patch clamp study on the same cells revealed an intermediate EC50 for ACh of approximately 10 µM and a shallow slope factor of 0.6, suggesting that these cells express a mixture of 4β2 nAChRs with high- and low-sensitivity for ACh (Wu et al., 2004). Taken together, the data seem to indicate that different labs find different pharmacological properties with the same cell line. An explanation for this could be that cell culture conditions vary between labs. It is known that the proportion of 4β2 nAChRs with high- and low-affinity for ACh depends on cell culture conditions (e.g., temperature during incubation of the cells) (Nelson et al., 2003; Zwart et al., 2006). Along these lines, it is possible that the major difference between the present findings on 4β2 nAChRs expressed in X. laevis oocytes and the previously published data on this compound (Xiao et al., 2006) in 4β2 nAChRs expressed in a mammalian cell line might be due to differences in the expression system used.
Our results help to understand and reconcile the recent reports on in vivo effects of sazetidine-A, showing that it acts as a quite typical 4β2 nAChR agonist in both drug discrimination (Xiao et al., 2007) and analgesic (Cucchiaro et al., 2007) assays. Although the contribution of additional subunits in native 4β2* nAChRs has not been excluded, the results are consistent with the hypothesis that in vivo effects of 4β2 nAChR agonists are mediated by native a4b2* nAChRs that have an 4(2)β2(3) stoichiometry.
|
Acknowledgements |
|---|
|
Footnotes |
|---|
Address correspondence to: Dr. Ruud Zwart, Eli Lilly and Company, Lilly Research Centre, Sunninghill Road, Windlesham, Surrey, GU20 6PH, United Kingdom. E-mail: zwart_ruud{at}lilly.com
|
References |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
Badio B and Daly JW (1994) Epibatidine, a potent analgesic and nicotinic agonist. Mol Pharmacol 45: 563-569.[Abstract]
Boyce S, Webb JK, Shepheard SL, Russell MGN, Hill RG, and Rupniak NMJ (2000) Analgesic and toxic effects of ABT-594 resemble epibatidine and nicotine in rats. Pain 85: 443-450.[CrossRef][Medline]
Briggs CA, Gubbins EJ, Marks MJ, Putman B, Thimmapaya R, Meyer MD, and Surowy CS (2006) Untranslated region-dependent exclusive expression of high-sensitivity subforms of 4β2 and 3β2 nicotinic acetylcholine receptors. Mol Pharmacol 70: 227-240.
Chavez-Noriega LE, Crona JH, Washburn MS, Urrutia A, Elliott KJ, and Johnson EC (1997) Pharmacological characterization of recombinant human neuronal nicotinic acetylcholine receptors h2β2, h2β4, h3β2, h3β4, h4β2, h4β4 and h7 expressed in Xenopus oocytes. J Pharmacol Exp Ther 280: 346-356.
Cucchiaro G, Gonzalez-Sulser A, Kozikowski AP, Kellar KJ, and Xiao Y (2007) Analgesic effects of sazetidine-A, a new nicotinic cholinergic drug. Anesthesiology 107: A1348.
Eaton JB, Peng JH, Schoeder KM, George AA, Fryer JD, Krishnan C, Buhlman L, Kuo YP, Steinlein O, and Lukas RJ (2003) Characterization of human 4β2 nicotinic acetylcholine receptors stably and heterologously expressed in native nicotinic receptor-null SH-EP1 human epithelial cells. Mol Pharmacol 64: 1283-1294.
Flores CM, Rogers SW, Pabreza LA, Wolfe BB, and Kellar KJ (1992) A subtype of nicotinic cholinergic receptors in rat brain is composed of 4 and β2 subunits and is upregulated by chronic nicotine treatment. Mol Pharmacol 41: 31-37.[Abstract]
Gerzanich V, Peng X, Wang F, Wells G, Anand R, Fletcher S, and Lindstrom J (1995) Comparative pharmacology of epibatidine: a potent agonist for neuronal nicotinic acetylcholine receptors. Mol Pharmacol 48: 774-782.[Abstract]
Grady SR, Salminen O, Laverty DC, Whiteaker P, McIntosh JM, Collins AC, and Marks MJ (2007) The subtypes of nicotinic acetylcholine receptors on dopaminergic terminals of mouse striatum. Biochem Pharmacol 74: 1235-1246.[CrossRef][Medline]
Jensen AA, Frolund B, Liljefors T, and Krogsgaard-Larsen P (2005) Neuronal nicotinic acetylcholine receptors: structural revelations, target identifications, and therapeutic inspirations. J Med Chem 48: 4705-4745.[CrossRef][Medline]
Ji J, Bunnelle WH, Anderson DJ, Faltynek C, Dyhring T, Ahring PK, Rueter LE, Curzon P, Buckley MJ, Marsch KC, et al. (2007) A-366833: A novel nicotinonitrile-substituted 3,6-diazabicyclo[3.2.0]-heptane 4β2 nicotinic acetylcholine receptor selective agonist: synthesis, analgesic efficacy and tolerability profile in animal models. Biochem Pharmacol 74: 1253-1262.[CrossRef][Medline]
Karadsheh MS, Shah MS, Tang X, MacDonald RL, and Stitzel JA (2004) Functional characterization of mouse 4β2 nicotinic acetylcholine receptors stably expressed in HEK293T cells. J Neurochem 91: 1138-1150.[CrossRef][Medline]
Khiroug SS, Khiroug L, and Yakel JL (2004) Rat nicotinic acetylcholine receptor 2β2 channels comparison of functional properties with 4β2 channels in Xenopus oocytes. Neuroscience 124: 817-822.[CrossRef][Medline]
Kuo YP, Xu L, Eaton JB, Zhao L, Wu J, and Lukas RJ (2005) Roles for nicotinic acetylcholine receptor subunit large cytoplasmic loop sequences in receptor expression and function. J Pharmacol Exp Ther 314: 455-466.
Lloyd GK and Williams M (2000) Neuronal nicotinic acetylcholine receptors as novel drug targets. J Pharmacol Exp Ther 292: 461-467.
López-Hernández GY, Sanchez-Padilla J, Ortiz-Acevedo A, Lizrdi-Ortiz JE, Salas-Vincenty J, Rojas LV, and Lasalde-Dominicci JA (2004) Nicotine-induced upregulation and desensitization of 4β2 neuronal nicotinic receptors depend on subunit ratio. J Biol Chem 279: 38007-38015.
Luetje CW and Patrick J (1991) Both - and β-subunits contribute to the agonist sensitivity of neuronal nicotinic acetylcholine receptors. J Neurosci 11: 837-845.[Abstract]
Luo S, Kulak JM, Cartier GE, Jacobsen RB, Yoshikami D, Olivera BM, and McIntosh JM (1998) -Conotoxin AuIB selectively blocks 3β4 nicotinic acetylcholine receptors and nicotine-evoked norepinephrine release. J Neurosci 18: 8571-8579.
Mogg AJ, Jones FA, Pullar IA, Sharples CGV, and Wonnacott S (2004) Functional responses and subunit composition of presynaptic nicotinic receptor subtypes explored using the novel agonist 5-iodo-A-85380. Neuropharmacology 47: 848-859.[CrossRef][Medline]
Moroni M, Zwart R, Sher E, Cassels BK, and Bermudez I (2006) 4β2 Nicotinic receptors with high and low acetylcholine sensitivity: pharmacology, stoichiometry, and sensitivity to long-term exposure to nicotine. Mol Pharmacol 70: 755-768.
Nelson ME, Kuryatov A, Choi CH, Zhou Y, and Lindstrom J (2003) Alternate stoichiometries of 4β2 nicotinic acetylcholine receptors. Mol Pharmacol 63: 332-341.
Papke RL (1993) The kinetic properties of neuronal nicotinic receptors: genetic basis of functional diversity. Prog Neurobiol 41: 509-531.[CrossRef][Medline]
Piciotto MR, Caldarone BJ, Brunzell DH, Zachariou V, Stevens TR, and King SL (2001) Neuronal nicotinic acetylcholine receptor subunit knockout mice: physiological and behavioral phenotypes and possible clinical implications. Pharmacol Ther 92: 89-108.[CrossRef][Medline]
Rupniak NMJ, Patel S, Marwood R, Webb J, Traynor JR, Elliott J, Freedman SB, Fletcher SR, and Hill RG (1994) Antinociceptive and toxic effects of (+)-epibatidine oxalate attributable to nicotinic agonist activity. Br J Pharmacol 113: 1487-1493.[Medline]
Salminen O, Murphy KL, McIntosh JM, Drago J, Marks MJ, Collins AC, and Grady SR (2004) Subunit composition and pharmacology of two classes of striatal presynaptic nicotinic acetylcholine receptors mediating dopamine release in mice. Mol Pharmacol 65: 1526-1535.
Smith JW, Mogg A, Tafi E, Peacey E, Pullar IA, Szekeres P, and Tricklebank M (2007) Ligands selective for 4β2 but not 3β4 or 7 nicotinic receptors generalise to the nicotine discriminative stimulus in the rat. Psychopharmacology 190: 157-170.[CrossRef][Medline]
Sullivan JP, Briggs CA, Decker MW, Brioni JD, Donnelly-Roberts D, Brioni JD, Radek RJ, McKenna DG, Campbell JE, Arneric SP, et al. (1994a) (±)-Epibatidine can differentially evoke responses mediated by putative subtypes of nicotinic acetylcholine receptors (nAChRs). Med Chem Res 4: 502-516.
Sullivan JP, Decker MW, Brioni JD, Roberts-Donnelly D, Anderson DJ, Bannon A, Gopalakrishnan M, Piattoni-Kaplan M, Adams P, Buchley MJ, et al. (1994b) (±)-Epibatidine elicits a diversity of in vitro and in vivo effects mediated by nicotinic acetylcholine receptors. J Pharmacol Exp Ther 271: 624-631.
Tapia L, Kuryatov A, and Lindstrom J (2007) Ca2+ permeability of the (4)3(β2)2 stoichiometry greatly exceeds that of (4)2(β2)3 human acetylcholine receptors. Mol Pharmacol 71: 769-776.
Wu J, Kuo YP, George AA, Xu L, Hu J, and Lukas RJ (2004) β-Amyloid directly inhibits human 4β2 nicotinic acetylcholine receptors heterologously expressed in human SH-EP1 cells. J Biol Chem 279: 37842-37851.
Xiao Y, Fan H, Musachio JL, Wei ZL, Chellappan SK, Kozikowski AP, and Kellar KJ (2006) Sazetidine-A, a novel ligand that desensitizes 4β2 nicotinic acetylcholine receptors without activating them. Mol Pharmacol 70: 1454-1460.
Xiao Y, Woolverton WL, Sahibzada N, Yasuda RP, and Kellar KJ (2007) Pharmacological properties of sazetidine-A, a desensitizer of 4β2 nicotinic acetylcholine receptors. Soc Neurosci Abstr 33: 574.6.
Young GT, Broad LM, Zwart R, Astles PC, Bodkin M, Sher E, and Millar NS (2007) Species selectivity of a nicotinic acetylcholine receptor agonist is conferred by two adjacent extracellular β4 amino acids that are implicated in the coupling of binding to channel gating. Mol Pharmacol 71: 389-397.
Zhou Y, Nelson ME, Kuryatov A, Choi C, Cooper J, and Lindstrom J (2003) Human 4β2 acetylcholine receptors formed from linked subunits. J Neurosci 23: 9004-9015.
Zwart R, Broad LM, Xi Q, Lee M, Moroni M, Bermudez I, and Sher E (2006) 5-I A-85380 and TC-2559 differentially activate heterologously expressed 4β2 nicotinic receptors. Eur J Pharmacol 539: 10-17.[CrossRef][Medline]
Zwart R and Vijverberg HPM (1998) Four pharmacologically distinct subtypes of 4β2 nicotinc acetylcholine receptors expressed in Xenopus laevis oocytes. Mol Pharmacol 54: 1124-1131.
This article has been cited by other articles:
|
|
 |
|
  H. Valette, Y. Xiao, M.-A. Peyronneau, A. Damont, A. P. Kozikowski, Z.-L. Wei, M. Kassiou, K. J. Kellar, F. Dolle, and M. Bottlaender 18F-ZW-104: A New Radioligand for Imaging Neuronal Nicotinic Acetylcholine Receptors--In Vitro Binding Properties and PET Studies in Baboons J. Nucl. Med., August 1, 2009; 50(8): 1349 - 1355. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Buccafusco, J. W. Beach, and A. V. Terry Jr. Desensitization of Nicotinic Acetylcholine Receptors as a Strategy for Drug Development J. Pharmacol. Exp. Ther., February 1, 2009; 328(2): 364 - 370. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|
 |
 |
 |
) and 
). Data are expressed as mean ± S.E.M. for three experiments.
). Sazetidine-A-evoked dopamine release is prevented in the presence of the nicotinic receptor antagonists dihydro-β-erythroidine (100 µM; 
) and mecamylamine (10 µM; 
). 